The Therapeutic Effect of Dysthyroid Optic Neuropathy

Status Recruiting

Clinical Trial Summary

Thyroid associated ophthalmopathy (TAO) is a common autoimmune disorder. The pathogenesis of TAO is unclear, and studies found that T cell, B cell and monocytes, macrophages and mast cells are located in the orbital tissue of TAO. Dysthyroid optic neuropathy (DON) is the most serious complication of TAO, which can cause blurred vision, color vision and vision function damage, and affects the quality of life. Investigation of the therapeutic effect of orbital decompression may provide some clues to make the policy at treatment of DON. We explore the therapeutic effect of orbital decompression in patients with DON in both eyes.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04096612
Study type	Interventional
Source	Sun Yat-sen University
Contact
Status	Recruiting
Phase	N/A
Start date	January 1, 2016
Completion date	December 31, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04583735` - A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease	Phase 4
Active, not recruiting	`NCT05002998` - TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study	Phase 4
Withdrawn	`NCT02422368` - The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease	Phase 2/Phase 3
Completed	`NCT03298867` - Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study	Phase 3
Recruiting	`NCT05987423` - A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease	Phase 3
Recruiting	`NCT06112340` - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)	Phase 2/Phase 3
Recruiting	`NCT05517447` - Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease	Phase 3
Terminated	`NCT04737330` - A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)	Phase 3
Recruiting	`NCT05517421` - Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease	Phase 3
Recruiting	`NCT04311606` - Anti-VEGF Therapy for Acute Thyroid Eye Disease	Phase 2
Recruiting	`NCT06106828` - A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease (SatraGO-2)	Phase 3
Recruiting	`NCT06021054` - A Randomized, Double-masked, Placebo-controlled Safety, Tolerability, and Efficacy Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants With Chronic Thyroid Eye Disease (TED)	Phase 3
Not yet recruiting	`NCT06413043` - Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy	N/A
Not yet recruiting	`NCT06401044` - A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease	Phase 1
Recruiting	`NCT06384547` - A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)	Phase 3
Recruiting	`NCT06367517` - Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)
Recruiting	`NCT06275373` - The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Enrolling by invitation	`NCT05241626` - AS-OCT of the Cornea in Thyroid Diseases
Active, not recruiting	`NCT05776121` - Study of ZB001 in Chinese Patients With Thyroid Eye Disease	Phase 1
Recruiting	`NCT04359979` - Tamsulosin for Thyroid Lid Retraction	N/A